DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rheumatoid Arthritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Rheumatoid Arthritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Rheumatoid Arthritis: An Overview
Rheumatoid arthritis (RA) is an autoimmune systemic inflammatory disorder that mainly affects the diarthrodial joint. It is the most common form of inflammatory arthritis and is characterized by inflammatory pathways that lead to the proliferation of synovial cells in joints. Overproduction of pro-inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-6, drives the destructive process. Subsequent pannus formation may lead to underlying cartilage destruction and bony erosions.
RA can affect multiple organs, such as the cardiovascular or respiratory systems; therefore, it is called a systemic disease. Rheumatoid arthritis most commonly affects the joints of the hands, feet, wrists, elbows, knees, and ankles. There is generally a bilateral/symmetrical pattern of disease progression (e.g., both hands or both knees are affected).
Rheumatoid Arthritis Market Key Facts
-
The total Rheumatoid Arthritis market size in the 7MM was USD 27 billion in 2021 and is projected to grow during the forecast period (2022-2032).
-
Among EU4 countries, Germany has the maximum revenue share in 2021, while Spain has the lowest market share.
-
The Rheumatoid Arthritis market size in Japan was found to be USD 3 billion in 2021, which is expected to rise during the forecast period (2022-2032).
-
The total market size of Rheumatoid Arthritis in the United States is expected to increase with a CAGR of 2.8% during the study period (2019–2032).
-
The total prevalent population of Rheumatoid Arthritis in the 7MM comprised 4,724,978 cases in 2021 and is projected to increase during the forecast period.
-
The total diagnosed prevalent cases of Rheumatoid Arthritis in the US were 1,256,779 in 2021
-
The United States contributed to the largest diagnosed cases of Rheumatoid Arthritis, accounting for ~ 30% of the 7MM in 2021.
-
Among EU4 countries, Germany accounted for the highest number of Rheumatoid Arthritis cases, whereas France accounted for the lowest number of cases in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Rheumatoid Arthritis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Rheumatoid Arthritis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Rheumatoid Arthritis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Rheumatoid Arthritis Epidemiology, Segmented as –
-
Prevalent cases of Rheumatoid Arthritis (RA) in 7MM (2019–2032)
-
Age-Specific cases of Rheumatoid Arthritis (RA) in 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Rheumatoid Arthritis (RA) in the 7MM (2019–2032)
-
Gender-specific cases of Rheumatoid Arthritis (RA) in the 7MM (2019–2032)
Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Rheumatoid Arthritis market or expected to be launched during the study period. The analysis covers the Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Rheumatoid Arthritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Latest Key Development in the Rheumatoid Arthritis Therapeutics Landscape
On 26 April 2023, SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”) announced that the Phase III clinical trial of its flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.: SM03-RA-III) had completed unblinding and initial statistical analysis and achieved the primary endpoint, marking a significant step towards Suciraslimab’s commercial launch.
Learn How the Rheumatoid Arthritis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Rheumatoid Arthritis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Rheumatoid Arthritis. Currently, RHEACELL is leading the therapeutics market with its Rheumatoid Arthritis drug candidates in the most advanced stage of clinical development.
The Leading Players in the Rheumatoid Arthritis Therapeutics Market Include:
I-Mab Biopharma Co. Ltd., ICMBIO, IGM Biosciences, Inc., Iltoo Pharma, Imcyse, Immutep Limited, Innocare Pharma Australia Pty Ltd, Intrinsic Medicine, Janssen Research & Development, Jiangsu Hengrui Medicine, Jubilant Therapeutics, Kangstem Biotech, Kiniksa Pharmaceuticals, Ltd., KLUS Pharma, Kolon TissueGene, Kymera Therapeutics, Landos Biopharma, Lynk Pharmaceuticals, Lysatpharma GmbH, Mesoblast, MetrioPharm, Minghui Pharmaceutical Pty Ltd, Modern Biosciences, MyMD Pharmaceuticals, Neutrolis Therapeutics, Novartis, NovImmune, Nurix, Oryn Therapeutics, Pfizer, Philogen, PrecisionLife, R-Pharm, Regen BioPharma Inc., RemeGen, Revolo Biotherapeutics, RheumaGen, ROS Therapeutics, Rottapharm Biotech, SciRhom, Servatus Biopharmaceuticals, SFA Therapeutics, Silo Pharma, SinoMab Bioscience Ltd, Sonoma Biotherapeutics, Sorrento Therapeutics, Synact Pharma, Synermore Biologics Co., Ltd., Taiho Pharmaceutical, Teijin Pharma, Tiziana Life Sciences, Vaccinex Inc., Vyne Therapeutics, Worg Pharmaceuticals, Yuyu Pharma, Inc., and others.
Rheumatoid Arthritis Emerging and Marketed Drugs Covered in the Report Include:
-
ABBV-3373: Abbvie
-
ABX464: Abivax
-
AP1189: Synact Pharma
-
Dazodalibep: Horizon Therapeutics
-
Dekavil: Philogen
-
ENBREL (etanercept): Immunex/Amgen
-
HUMIRheumatoid Arthritis (adalimumab): AbbVie
-
OLUMIANT (barticinib): Eli Lilly/Incyte Corporation
-
Otilimab (GSK3196165/MOR103): GlaxoSmithKline
-
PF-06650833: Pfizer
-
Rabeximod (Rob 803): Cyxone
-
RC18: RemeGen
-
RINVOQ (upadacitinib): AbbVie
-
SHR0302: Jiangsu Hengrui Medicine
-
SM03: SinoMab
-
Zalunfiban: CeleCor Therapeutics
-
Zunsemetinib (ATI-450): Aclaris Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Rheumatoid Arthritis Competitive Intelligence Analysis
4. Rheumatoid Arthritis Market Overview at a Glance
5. Rheumatoid Arthritis Disease Background and Overview
6. Rheumatoid Arthritis Patient Journey
7. Rheumatoid Arthritis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Rheumatoid Arthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Rheumatoid Arthritis Unmet Needs
10. Key Endpoints of Rheumatoid Arthritis Treatment
11. Rheumatoid Arthritis Marketed Products
12. Rheumatoid Arthritis Emerging Drugs and Latest Therapeutic Advances
13. Rheumatoid Arthritis Seven Major Market Analysis
14. Attribute Analysis
15. Rheumatoid Arthritis Market Outlook (In US, EU5, and Japan)
16. Rheumatoid Arthritis Access and Reimbursement Overview
17. KOL Views on the Rheumatoid Arthritis Market
18. Rheumatoid Arthritis Market Drivers
19. Rheumatoid Arthritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/